LONG-TERM SURVIVORS OF SIV/HIV INFECTION

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 被分配给这个项目的动物已经成功地感染了灵长类慢病毒。目的是在更长一段时间内继续进行健康、病毒学和免疫学监测。目前的动物感染艾滋病毒-1已超过16年，所有动物都继续对艾滋病毒-1蛋白表现出血清阳性反应。这一持续但受控的HIV-1复制的迹象促使我们设计了一项实验，通过用人源化的小鼠抗CD8单抗Cm-T807治疗体内的CD8+细胞来暂时耗尽CD8+细胞，从而检查CD8+细胞在病毒控制中的作用。一般来说，CD8耗尽的病毒控制猕猴经历了病毒复制的显著增加，然后当CD8+细胞恢复到治疗前的水平时，又重新控制了病毒。这种病毒复制的高峰可能会使分离的病毒物种具有特征性，并可能进一步传代和适应，这将有助于开发利用导致人类疾病的相同病毒的非人类灵长类艾滋病模型，这是艾滋病毒疫苗和治疗设计领域的研究人员期待已久的目标。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Animals assigned to this project have been successfully infected with a primate lentivirus. The purpose is to continue health, virologic and immunologic monitoring for an extended period of time. The current animals have been infected with HIV-1 over 16 years at this time, and all continue to demonstrate seropositive responses to HIV-1 proteins. This indication of continuing but controlled HIV-1 replication has led us to design an experiment to examine the role of CD8+ cells in virus control by temporarily depleting CD8+ cells in vivo by treatment with the humanized mouse monoclonal anti-CD8 antibody, cM-T807. Generally, CD8-depleted virus-controlling macaques experience a coincident marked increase in virus replication and then regain control when CD8+ cells return to pretreatment levels. This spike of virus replication may permit the characterization and possible further passage and adaptation of viral species isolated, which would aid in the development of a non-human primate model for AIDS utilizing the same virus that causes disease in humans, a long-desired goal of researchers in the field of HIV vaccine and therapeutics design.